Effective doses of paliperidone palmitate (PAP): Retrospective analysis from three years of treatment

2016 ◽  
Vol 33 (S1) ◽  
pp. S540-S540
Author(s):  
S. Galiano Rus ◽  
A. Soler Iborte ◽  
C. Quesada González
Keyword(s):  
Mental Health ◽  
Clinical Practice ◽  
Hospital Admissions ◽  
Average Length ◽  
Average Hospital ◽  
Icd 10 ◽  
Effective Doses ◽  
Technical Specifications ◽  
Competing Interest ◽  
Long Acting

IntroductionThe use of PAP is already much extended in general. The recommended doses in the technical specifications of the drugs, as the result of trial studies, differ from the doses administered in habitual clinical practice. Therefore, the justification of this study is to monitor the average doses prescribed, to be able to reach an agreement on the best doses. To retrospectively analyze the first 32 patients in our area of healthcare, who were prescribed PAP, the doses used at the start of treatment and after 3 years.Materials and methodsTwo initial doses of PAP were analyzed, maximum and current (outpatient) in 32 patients attended in the area of mental health of North Jaen, who started the treatment with PAP between 2012 and 2013, with an average length of time of 2.55 years (SD 2.02). We evaluated the diagnosis (schizophrenia and related disorders, ICD-10 F20), the number of hospital admissions previous and posterior to the start of the treatment and change in weight.ResultsAverage doses: initial: 110.15 mg (SD 32.83), maximum: 165.51 mg (SD 29.76) and maintenance: 146.81 mg (SD 29.59). Average hospital admissions: prior and posterior to the start of treatment: 1.5 and 0.83. An average reduction of 44.06% in admissions was observed.ConclusionsThe data obtained suggests that a dose of 75–200 mg could be effective in the maintenance of patients with schizophrenia and for decreasing the number of new hospital admissions. Fifty percent of the cases can be compensated with long acting peliperidone as a monotherapy.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Hospital admissions and direct costs: A comparative study between paliperidone palmitate and oral antipsychotics

2016 ◽  
Vol 33 (S1) ◽  
pp. s229-s229
Author(s):  
A. Soler Iborte ◽  
S. Galiano Rus ◽  
J.A. Ruíz Sánchez
Keyword(s):  
Hospital Stay ◽  
Hospital Admissions ◽  
Average Length ◽  
Direct Costs ◽  
Average Hospital Stay ◽  
Average Hospital ◽  
Number Of Patients ◽  
Icd 10 ◽  
Schizophrenic Patients ◽  
Competing Interest

IntroductionThe total costs of schizophrenia increased to 2576 million Euros in 2013 in Spain, or 2.7% of the annual cost of health services. The hospitalizations, along with other intermediate resources, such as Day Hospital, etc., significantly contribute to the increase of economic burden. In Spain, the average hospital stay of schizophrenic patients is 18.24 days, totalling to an average cost of 6,753 Euros/patient (370.23 Euros/patient/day).Material and methodsThe sample selected included patients from both sexes, aged between 18 and 65 years old, with diagnostic criteria of schizophrenia (according to DSM-IV and ICD-10), admitted in the Mental Health Hospital Unit (MHHU), Úbeda between 2012 and 2013, with registered visits of at least 2 outpatient visits or 1 hospitalization related to the schizophrenia diagnosis (n = 48).ResultsAfter the start of treatment with the injectable antipsychotic drug of prolonged duration, the number of patients that required hospitalization for any psychiatric motive went from 24 patients (49.7%) to 11 patients (22.4%; P < 0.001). The patients who started treatment with PAP during hospitalization had an average stay of 15.7 days, as compared to 18.24 days of average hospital stay due to schizophrenia in Spain. The direct costs of hospitalization stays due to psychiatric reasons decreased from 162,071.88 Euros to 74,282.95 Euros (P < 0.001).ConclusionsThis observational study shows us that the treatment with PAP reduced the average length of the hospital stay, and resulted in a decreased percentage of re-admissions as compared to oral treatments for schizophrenia. These data led to savings of more than 50% of the direct costs of hospitalization.Disclosure of interestThe authors have not supplied their declaration of competing interest.

A pharmacologic option to reduce hospital admissions and relapses of patients with severe mental illness

2017 ◽  
Vol 41 (S1) ◽  
pp. S753-S753
Author(s):  
N. Gomez-Coronado ◽  
P. Blanco ◽  
I. Martinez
Keyword(s):  
Mental Health ◽  
Hospital Admissions ◽  
Descriptive Analysis ◽  
Psychotic Episode ◽  
Anti Psychotic ◽  
Before And After ◽  
Previously Treated ◽  
Competing Interest ◽  
One Year ◽  
Long Acting

IntroductionSome diseases relapses involve functional impairment that sometimes takes years to recover. We present our experience using long-acting aripiprazole as maintenance therapy in patients diagnosed with psychotic episode, acute mania (bipolar disorder) or personality disorder, who were previously treated with another anti-psychotic.AimsAnalyze what treatment were they taking before aripiprazole depot. Determine the number of hospital admissions and relapses before and after long-acting aripiprazole treatment.MethodsDescriptive analysis based on a sample of 37 patients, aged 18–65 years, treated during one year with anti-psychotics at two community mental health units.ResultsReduction of hospitalization average: 0.59/year with non-long-acting-aripiprazol anti-psychotic, 0.18/year with long-acting aripiprazol (66.6%).ConclusionLong-acting aripiprazole appears to reduce the number of hospitalizations and relapses compared to other anti-psychotics. However, the sample size is small and more studies are needed.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Recent Critical Trends in Mental Hospital Admissions in the Oxford Region

1962 ◽  
Vol 108 (452) ◽  
pp. 59-67 ◽  
Author(s):  
A. Barr ◽  
D. Golding ◽  
R. W. Parnell
Keyword(s):  
Mental Health ◽  
Length Of Stay ◽  
Mental Hospital ◽  
Hospital Admissions ◽  
Average Length ◽  
Time Study ◽  
Ministry Of Health ◽  
Mental Hospitals ◽  
Average Length Of Stay ◽  
One Year

The statistics on mental hospitals published by the Ministry of Health (1957) show that the average length of stay for admissions to mental hospitals decreased in the period 1952–1956. According to the Registrar-General's Mental Health Supplement (1961) there was an average saving, between 1951 and 1958, of sixteen days for men and thirteen days for women, among patients staying less than one year. But these figures for stay only relate to the patients discharged each year, irrespective of the year of their admission, and furthermore we do not know what happens to particular groups such, for example, as schizophrenics. Although remarkable changes are occurring at the present time, study of them is hampered by lack of appropriate and up-to-date information.

Paliperidone palmitate: Experience in a community mental health unit

2017 ◽  
Vol 41 (S1) ◽  
pp. s804-s805
Author(s):  
L. Carrión Expósito ◽  
G.M. Chauca Chauca ◽  
E.L. Guadalupe
Keyword(s):  
Mental Health ◽  
Retrospective Study ◽  
Maintenance Dose ◽  
Lower Number ◽  
Paliperidone Palmitate ◽  
Health Unit ◽  
Dose Number ◽  
Competing Interest ◽  
Long Acting ◽  
Mental Health Unit

IntroductionThere are many jobs that offer advantages of treatment with long-acting injectable in psychosis.ObjectiveTo know the changes in the different variables after the start of paliperidone palmitate (PP).Material and methodWe performed a descriptive and retrospective study. Were evaluated patients who received maintenance therapy with PP during 48 months.ResultsThe sample was composed of 29 patients: 72.4% men and 27.6% women. Average age of 46.21 years. In Figures 1, 2 and 3 show data obtained in relation to compliance with treatment, relapse, maintenance dose, number of admissions and visits to emergency departments respectively.ConclusionsThe administration of PP is associated with a higher level of compliance with treatment. The patients presented a lower number of relapses, hospitalizations and visits to the emergency room. The maintenance dose more used is 150 mg.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Paliperidone Palmitate Study in Patients With Personality Disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S505-S505
Author(s):  
M.A. Gutierrez Ortega ◽  
D.P. María Dolores ◽  
M.A. Manuel ◽  
M.M. Esther
Keyword(s):  
Personality Disorder ◽  
Personality Disorders ◽  
Hospital Admissions ◽  
Average Length ◽  
Paliperidone Palmitate ◽  
Emergency Visits ◽  
Actual Clinical Practice ◽  
Average Length Of Stay ◽  
Psychopharmacological Treatment ◽  
Competing Interest

IntroductionPersonality disorders are chronic affectation of mood, impulsivity, aggression and anxiety. It is thought to have biological factors related to the development of personality disorders.AimsTo evaluate and compare the efficacy of injectable paliperidone in actual clinical practice of patients diagnosed with Personality Disorder, compared to other treatments.MethodsWe conducted a descriptive, restrospective and observational study from January 2012 to June 2015 including all the patients who are treated with paliperidone palmitate extended-release injectable suspension with a diagnosis of Personality Disorder according to DSM 5. We included patients with at least 12 months of treatment and the results were compared with respect to the 12 months prior to taking said drug. Variables studied: medical diagnosis, hospital admissions, average length of stay, total number of emergency visits or other devices, maintenance doses.ResultsWe recruited 14 patients (7 women and 7 men) with a mean age of 36.2. 64.29% of patients had borderline personality disorder; 21.43% unspecified personality disorder. The mean dose of maintenance treatment is 105.357. Before the treatment, the quantity of total number of hospital admission are 1.14 versus 0.429 after treatment. The number of stay is also decreased from 13.7 to 3.5; like emergency room visits or to other devices. 78.57% of patients continue to psychopharmacological treatment. Fifty percent of patients undergoing treatment with another antipsychotic (P < 0.05).ConclusionsThe present results show that paliperidone palmitate can be an effective way to control the most characteristic symptoms of Personality Disorders, and reducing emergency visits, hospitalisations and other devices.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Long acting injectable aripiprazole: An observational study

2017 ◽  
Vol 41 (S1) ◽  
pp. S753-S753
Author(s):  
N. Garcia ◽  
J. Brotons ◽  
R. Genoves ◽  
J. Martinez-Raga ◽  
C. Saez ◽  
...  
Keyword(s):  
Emergency Room ◽  
Clinical Outcomes ◽  
Treatment Adherence ◽  
Maintenance Treatment ◽  
Average Length ◽  
Health Resources ◽  
University Hospital ◽  
Emergency Room Visits ◽  
Competing Interest ◽  
Long Acting

IntroductionSeveral trials have shown the efficacy of long acting injectable (LAI) second-generation anti-psychotics compared with other anti-psychotics. LAI aripiprazole is a novel therapeutic tool in the management of patients with schizophrenia.AimsThe present study aimed to evaluate the clinical outcomes of patients who initiated treatment with LAI aripiprazole, by comparing their clinical outcomes prior and after initiating treatment with LAI aripiprazole.MethodsThis observational, retrospective, mirror study assessed a series of socio-demographic and clinical variables during the 12 months prior to commencing LAI aripiprazole, while on another anti-psychotic medication, and the first 12 months of LAI aripiprazole. The sample included a series of consecutive patients receiving LAI aripiprazole at the Doctor Peset university hospital health area, in Valencia (Spain). The variables analyzed in the study included: emergency room visits, number and average length of hospitalizations, relapse, rate of abandonment of treatment and number of anti-psychotics needed as maintenance treatment.ResultsThe preliminary analysis showed a reduction in the rate of emergency room visits and the number of relapse and total hospitalizations while on LAI aripiprazole; however, there is no a reduction of the average length of hospitalizations. A reduction in the number of anti-psychotics as maintenance treatment was not appreciated, however, there was an improvement in treatment adherence.ConclusionsThe preliminary results showed that LAI aripiprazole is an useful option that could suppose a benefit concerning treatment adherence, a decreased in number of relapses and hospitalizations and use of health resources.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Patients with severe schizophrenia. functioning improvement after 7-year of comprehensive treatment

2017 ◽  
Vol 41 (S1) ◽  
pp. S195-S195
Author(s):  
J.J. Fernandez-Miranda ◽  
S. Díaz-Fernández ◽  
D.F. Frías-Ortiz
Keyword(s):  
Treatment Adherence ◽  
Psychosocial Functioning ◽  
Hospital Admissions ◽  
Functional Improvement ◽  
Comprehensive Treatment ◽  
Good Tolerability ◽  
Time In Treatment ◽  
Competing Interest ◽  
Retention In Treatment ◽  
Long Acting

IntroductionTo reach not only clinical but also rehabilitation (especially to improve psychosocial functioning) goals in people with schizophrenia is a need.ObjectiveTo know the retention in treatment and functional outcomes of patients with severe schizophrenia enrolled in a specific and comprehensive programme for 7 years.MethodA 7-year prospective, observational study of patients with severe schizophrenia (CGI-S of 5 or over) undergoing comprehensive programme (n = 200). Assessment included at the beginning and after 3, 6, 12, 24, 36 and 84 months: the CGI-S, the Camberwell Assessment of Needs (CAN) and the WHO-DAS. Time in treatment, reasons for discharge, laboratory tests, weight, medications, adverse effects and hospital admissions in the previous six years and during the follow-up were registered.ResultsCGI at baseline was 5.9 (0.7). After seven years, 44% of patients continued under treatment (CGI = 4.3 (0.8); P < 0.01); 36% were medical discharged (CGI = 3.4 (1.5); P < 0.001); WHO-DAS decreased in the four areas (P < 0.005) and also CAN (P < 0.01); 8% were voluntary discharges. Ten patients dead; three of them committed suicide (1.5%). Hospital admission decreased significantly (P < 0.001), and also antipsychotic combinations and antiparkinsonian medications. Fifty-five percent of all of them were treated with atypical long-acting antipsychotics, with good tolerability and few side effects (among them, only 4% were voluntary discharges).ConclusionRetention of patients with schizophrenia with severe symptoms and impairment in a specific and comprehensive programme was really high. Such good treatment adherence helped to get remarkable clinical and functional improvement. Long-acting medication seemed to be useful in improving treatment adherence.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Community Mental Health: Description of the Patients Concerning the Uls Guarda Department of Psychiatry and Mental Health Area

2016 ◽  
Vol 33 (S1) ◽  
pp. S452-S452
Author(s):  
J. Nunes ◽  
J. Feliz ◽  
D. Brigadeiro ◽  
T. Ventura Gil ◽  
A.F. Teixeita ◽  
...  
Keyword(s):  
Mental Health ◽  
Community Mental Health ◽  
Hospital Admissions ◽  
Psychiatric Patients ◽  
World Health ◽  
Mental Health Team ◽  
Mental Problems ◽  
The World ◽  
Competing Interest ◽  
Health Organization

The World Health Organization (WHO, 2004) stresses the importance of home patient visiting as an answer to the epidemiologic, demographic, social and economic challenges that the world is facing.The severe psychiatric patients are a risk group and often need domicile consultation and visiting. The domicile consultation approach favors the clinical, social and familiar support as well as promotes the integration and the recovering of the patients with mental problems, preventing the relapses and the hospital admissions of these patients.This study, of descriptive nature, is based on the observation and consultation of 287 clinical processes of patients inserted in the domicile consultation program designed by the Department of Psychiatry and Mental Health of Sousa Martins Hospital, ULS Guarda, which covers the 7th biggest district in Portugal (in a universe of 18), between July and September 2015.The main goal of this study is to characterize and analyze the profile of the population, which is followed by the community mental health team of our Department, namely, the socio-demographic and clinic features, in order to improve the assistance practice in the future.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Time to relapse monotherapy and acquisition in a sample of schizophrenic patients over 3 years of follow-up

2016 ◽  
Vol 33 (S1) ◽  
pp. s261-s261
Author(s):  
P. González Rivera ◽  
A.J. Benito Ruiz ◽  
J. Prados Gomez ◽  
A. Hidalgo Borreguero ◽  
M. Soto Laguna ◽  
...  
Keyword(s):  
Concomitant Medication ◽  
Hospital Admissions ◽  
Clinical Sample ◽  
Psychiatric Patients ◽  
Clinical Relapse ◽  
Adherence To Treatment ◽  
Schizophrenic Patients ◽  
Competing Interest ◽  
Long Acting ◽  
Time To Relapse

IntroductionPoor adherence to treatment is one of the main problems in health care to psychiatric patients. The second-generation antipsychotics, and the subsequent emergence of the depot forms (long acting formulations) have facilitated this aspect, increasing the time to clinical relapse in patients with schizophrenia.GoalsDetermine the time to relapse in a clinical sample of patients diagnosed with schizophrenia treated with paliperidone palmitate over 3 years. Other objectives include the possible reduction in hospital admissions, as well as the possible reduction of psychiatric emergency visits, concomitant medication (benzodiazepines and Biperiden) and the possible increase in drug monotherapy.MethodologyThis is a study with a sample of 101 patients with schizophrenia who had started treatment with PP (consecutive sampling). Quantified variables in the 12 months prior to the change of PP treatment with variables at 6, 12, 24 and 36 months after initiation of treatment with PP were compared.Results and conclusionsAt the end of the tracking, 72.22% (73 patients) remained clinically stable, with adequate adherence to treatment and there have been no clinical relapses. It has obtained a statistically significant reduction in the use of concomitant medication, emergency room visits and the average duration of revenues, with no clinical relapse should occur in patients of the sample in the second and third year.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Sign in / Sign up

Export Citation Format

Share Document